Jennifer L. Good - 10 May 2024 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
President & CEO, Director
Signature
/s/ Christopher Galletta, attorney-in-fact
Issuer symbol
TRVI
Transactions as of
10 May 2024
Net transactions value
-$3,250
Form type
4
Filing time
14 May 2024, 16:51:46 UTC
Previous filing
16 Feb 2024
Next filing
22 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRVI Common Stock Options Exercise $10,026 +4,578 +2.1% $2.19 217,891 10 May 2024 Direct F1
transaction TRVI Common Stock Sale $13,276 -4,578 -2.1% $2.90 213,313 10 May 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Options Exercise $0 -4,578 -7.3% $0.000000 58,226 10 May 2024 Common Stock 4,578 $2.19 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 7,109 shares purchased through the Issuer's employee stock purchase plan.
F2 This option was granted on July 2, 2014. The 62,804 shares of common stock underlying the option vested as to 25% of the shares on June 11, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through June 11, 2018.